Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology & Therapeutics (Aliment. Pharmacol. Ther.) is a gastroenterology and hepatology journal published by Wiley-Blackwell, part of John Wiley & Sons. Founded in 1987, it has been online-only since 2018 with about twenty-three issues a year, concentrates on drug and treatment research in clinical gastroenterology and hepatology, and had a 2025 impact factor of 6.8.《消化药理学与治疗学》（Alimentary Pharmacology & Therapeutics''''，缩写 Aliment. Pharmacol. Ther.''）是约翰威立旗下（Wiley-Blackwell）出版的胃肠病学与肝病学刊物，1987 年创刊，2018 年起改为纯在线出版、每年约二十三期。该刊以临床胃肠与肝病的药物与治疗研究为主，二〇二五年影响因子为 6.8。
Scope
The journal defines itself as a bench-to-bedside gastroenterology and hepatology title: whatever stage a study occupies, mechanism, diagnosis or treatment, it must have a counterpart in clinical practice, and the subjects must be human. Case reports are explicitly excluded, and the principal areas are:本刊的定位是「从实验室到病床」的胃肠病学与肝病学刊物：一项研究无论落在机制、诊断还是治疗环节，都必须能在临床处境中找到对应，且研究对象须为人体。编辑部明确不收病例报告，收文重点包括：
- Clinical gastroenterology: inflammatory bowel disease, functional gastrointestinal disorders and motility, Helicobacter pylori and acid-related disease, and evaluation of endoscopic and interventional treatment.临床胃肠病学： 炎症性肠病、功能性胃肠病与动力障碍、幽门螺杆菌与酸相关疾病、内镜与介入治疗的评价。
- Clinical hepatology: viral hepatitis and antiviral therapy, metabolic dysfunction-associated steatotic liver disease, cirrhosis and portal hypertension, and liver transplantation and failure.临床肝病学： 病毒性肝炎与抗病毒治疗、代谢相关脂肪性肝病、肝硬化与门脉高压、肝移植与肝衰竭。
- Drugs and therapeutics: clinical trials and dose-finding for new agents, drug interactions and pharmacokinetics, and comparison of treatment strategies with health technology assessment.药物与治疗学： 新药临床试验与剂量研究、药物相互作用与药代动力学、治疗策略的比较与卫生技术评估。
- Diagnosis and screening: non-invasive diagnostic markers, imaging and endoscopic technique, and health-economic assessment of screening strategies and diagnostic pathways.诊断与筛查： 非侵入性诊断标志物、影像与内镜诊断技术、筛查策略与早诊路径的卫生经济学评价。
- Pharmacoepidemiology and safety: real-world studies of adverse drug reactions, population comparisons of risk and benefit, and pharmacovigilance with signal detection.药物流行病学与安全性： 药物不良反应的真实世界研究、用药风险与获益的人群比较、药物警戒与信号检测。
- Translational and mechanistic work: mucosal immunity and the microbiome, molecular pathways of tumourigenesis, and mechanistic studies validated in human material.转化与机制研究： 黏膜免疫与微生物组、肿瘤发生的分子通路、以人体样本验证的机制研究。
The journal is hybrid and authors may pay an article processing charge to publish open access. The publisher reports an acceptance rate of about seventeen per cent in 2025 and a median of two days from submission to first decision, a figure that includes editorial screening.本刊为混合出版，作者可选择支付文章处理费以开放获取发表；出版方公布 2025 年录用比例约百分之十七，投稿至首次决定的中位数为两天，该时长包含编辑部初筛。[1]
History
- Founding (1987): the journal was founded in 1987 by Roy Pounder and colleagues, published by Blackwell Scientific Publications as a print bimonthly, and conceived from the start as a dedicated venue for pharmacological and therapeutic research in gastroenterology.创刊（1987年）： 1987 年由（Roy Pounder）等人创办，创刊时由（Blackwell Scientific Publications）出版，为双月印刷刊，定位即为胃肠病学的药理学与治疗研究提供专门园地。[2]
- Publishing history: publication passed from Blackwell Scientific to Blackwell Publishing and then, with that house's absorption into John Wiley & Sons, to Wiley-Blackwell. The title has never changed and the volume numbering is continuous.出版方沿革： 出版方由（Blackwell Scientific）转为（Blackwell Publishing），再随该社并入约翰威立，现以（Wiley-Blackwell）名义出版；刊名自创刊起未曾变更，卷号连续。[3]
- Move online (2018): in January 2018 the journal dropped its print edition and became online-only, with the issue count rising to about twenty-three a year, a change that also removed the length constraints imposed by print.转为纯在线（2018年）： 2018 年 1 月起本刊停止印刷版、改为纯在线出版，期数随之加密至每年约二十三期，这一改动同时取消了印刷版对篇幅的限制。[4]
- Metrics and indexing: the 2025 impact factor is 6.8, with a CiteScore of 14 and a journal citation indicator of 1.69, and the journal carried some 580 papers in 2025. It is indexed in the Science Citation Index Expanded, Scopus and MEDLINE.指标与收录： 2025 年影响因子 6.8、引用分数 14、期刊引文指标 1.69，2025 年刊载论文五百余篇；本刊被科学引文索引扩展版、Scopus 与 MEDLINE 收录。[1]
Editors
The journal is run by two editors based at different North American institutions, one covering gastroenterology and the other hepatology, an arrangement that matches the journal's dual gastroenterological and hepatic remit本刊由两名编辑共同主持，两人分处北美不同机构，分别覆盖胃肠病学与肝病学两个方向，这一安排与刊物「胃肠加肝脏」的双重定位相匹配；创刊后在很长时间里由创刊人一人长期主持。 for a long period after its founding it was led by the founder alone.[2]
- Present editors (since 2018): C. W. Howden of the University of Tennessee Health Science Center and Rohit Loomba of the University of California San Diego have run the journal jointly since 2018, handling gastroenterological and hepatological submissions respectively.现任编辑（2018年起任）： （C. W. Howden）供职于田纳西大学健康科学中心，（R. Loomba）供职于加利福尼亚大学圣迭戈分校，两人自 2018 年起共同主持本刊，分别主管胃肠病学与肝病学方向的稿件。[2]
- Founding editor: Roy E. Pounder led the journal from its 1987 launch until 2017 and was the central figure in its first three decades. The publisher does not give exact terms for the other editors who served alongside him.创刊主编： （Roy E. Pounder）自 1987 年创刊起长期主持本刊，任期至 2017 年，是本刊三十年发展中最主要的人物；出版方未完整公布其间其他主编的确切任期。[2]
- Role in the field: the journal has long been one of the principal outlets for drug trials and pharmacoepidemiological studies in gastroenterology, and its refusal of case reports and insistence on human studies give it unusually clear boundaries among titles of its kind.学科角色： 本刊长期是胃肠病学界发表药物临床试验与药物流行病学研究的主要园地之一，其不收病例报告、只收人体研究的取向，使其在同类刊物中边界清晰。[5]